Accessibility Menu
Ucb logo

Ucb(OTC) UCBJY

Market Cap$47.44BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2010)+784%
5 Year+130%
1 Year+11%
1 Month-8%
$126.00
+1.28%
+1.59Today
Ucb last closing stock price
MetricPriceDate
Last closeUSD 126.002026-08-18
Ucb stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-3.41%USD 130.452026-08-11
1 month-7.79%USD 136.652026-07-17
3 month-9.2%USD 138.772026-05-20
Year to date-9.27%USD 138.872025-12-31
1 year+11.29%USD 113.222025-08-18
3 year+195.92%USD 42.582023-08-18
5 year+130.25%USD 54.722021-08-19
Since inception+783.74%USD 14.082010-06-18

Ucb Financials at a Glance

Market Cap

$47.44BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

€15.43B

Net Income (TTM)

€3.54B

EPS (TTM)

$6.59

P/E Ratio

18.51

Dividend

$0.85

Beta (Volatility)

0.44 (Low)

Price

$126.00

Volume

22,405

Open

$124.55

Previous Close

$126.00

Daily Range

$124.42 - $126.00

52-Week Range

$111.72 - $168.76

Estimated Earnings Date

Feb 25, 2027

UCBJY News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Ucb

UCB S.A. is a biopharmaceutical company focused on developing innovative treatments for neurological and immunological diseases. The company offers a diverse portfolio of products aimed at addressing various health conditions, including inflammatory diseases and epilepsy.

Products and Services
  • Cimzia for inflammatory TNF-mediated conditions
  • Vimpat, Keppra, and Briviact for epilepsy management
  • Neupro for Parkinson's disease and restless legs syndrome
Growth Outlook
  • Recent quarterly revenue reached €4.22 billion, indicating strong demand
  • Robust development pipeline with therapies for Alzheimer's and myasthenia gravis
  • Collaborative agreements with major partners enhance market reach
Financial Highlights
  • Trailing twelve months (TTM) revenue of €13.5 billion reflects consistent growth
  • Net income margin of 25.7% demonstrates effective cost management
  • Operating cash flow of €1.55 billion supports ongoing investments
UCB S.A. has established itself as a key player in the biotechnology sector, with a strong emphasis on research and development. The company's commitment to innovation is evident in its extensive product offerings and ongoing clinical trials. Recent financial performance highlights a solid revenue base and profitability, positioning UCB favorably for future growth. The strategic partnerships with industry leaders further enhance its capabilities and market presence, making it an attractive option for investors interested in the biopharmaceutical landscape.
AI Generated • Aug 1, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

10,117

CEO

Jean-Christophe Tellier, MD

Website

www.ucb.com

Headquarters

Brussels, BU 1070, BE

UCBJY Financials

Key Financial Metrics (TTM)

Gross Margin

76.23%

Operating Margin

31.23%

Net Income Margin

25.74%

Return on Equity

19.48%

Return on Capital

8.55%

Return on Assets

10.63%

Earnings Yield

5.40%

Dividend Yield

0.68%

Payout Ratio

12.58%

Stock Overview

Market Cap

$47.44BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

381.33M

Volume

22.41K

Avg. Volume

36.25K

Financials (TTM)

Gross Profit

€11.31B

Operating Income

€4.40B

EBITDA

€5.69B

Operating Cash Flow

€3.46B

Capital Expenditure

-€735.96M

Free Cash Flow

€2.72B

Cash & ST Invst.

€796.67M

Total Debt

€3.59B

Ucb Performance Analysis

Ucb annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31EUR 5,798,225,305-15.1%
20232023-12-31EUR 5,678,019,147-2.1%
20242024-12-31EUR 6,654,561,53317.2%
20252025-12-31EUR 8,736,321,91631.3%
Ucb sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-3120.4%
Q22025-06-303.7%
Q42025-12-3121.1%
Q22026-06-303.1%
Ucb annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31EUR 1.13-65.0%
20232023-12-31EUR 0.95-15.7%
20242024-12-31EUR 2.96211.7%
20252025-12-31EUR 4.5352.9%
Ucb sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31312.1%
Q22025-06-30-44.7%
Q42025-12-31126.6%
Q22026-06-305.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

€4.35B

+56.0%

Gross Profit

€3.25B

+67.5%

Gross Margin

74.64%

N/A

Market Cap

$47.44BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$4.69M

N/A

Employees

10,117

N/A

Net Income

€1.13B

+444.7%

EBITDA

€1.77B

+174.9%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

€796.67M

+86.1%

Total Debt

€3.59B

+18.1%

Accounts Receivable

€2.58B

+88.7%

Inventory

€1.74B

+53.1%

Long Term Debt

€3.37B

+12.9%

Short Term Debt

€216.91M

+301.7%

Return on Assets

10.63%

N/A

Return on Invested Capital

16.54%

N/A

Free Cash Flow

€84.65M

-67.6%

Operating Cash Flow

€327.38M

-13.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
LZAGFLonza Group AG
$702.51+0.01%
LZAGYLonza Group AG
$69.56-0.23%
HLNCFHaleon plc
$4.82-3.31%
CMXHFCSL Limited
$111.29+13.53%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.48-0.02%
INTCIntel
$96.69-0.07%
NOKNokia
$10.39-0.04%
NVDANvidia
$219.74-0.02%

Questions About UCBJY

What is the current price of Ucb?

Ucb is trading at $126.00 per share.

What is the 52-week range for Ucb?

Over the past 52 weeks, Ucb has traded between $111.72 and $168.76.

How much debt does Ucb have?

As of the most recent reporting period, Ucb reported total debt of €2.64B.

How much cash does Ucb have on hand?

Ucb reported €2.64B in cash and cash equivalents in its most recent financial results.

What is Ucb’s dividend yield?

Ucb currently has a dividend yield of 0.68%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services